ONCAlert | Upfront Therapy for mRCC
Latest From SITC
An Overview of an Immuno-Oncology Panel for Standardized Profiling of Immune Status
2:55 PM, Wed November 15, 2017
CAR T-Cell Therapy Hits Prime Time; Challenges Remain
3:47 PM, Mon November 13, 2017
Nivolumab/Ipilimumab Combo May Hold Potential in Neoadjuvant Melanoma
3:29 PM, Sun November 12, 2017
Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers
7:21 PM, Sat November 11, 2017
Using Antibody-Mediated Neutralization of Soluble MIC to Enhance Response to CTLA-4 Blockade
11:43 PM, Fri November 10, 2017
Manipulating Dendritic Cells for Cancer Immunity
9:49 PM, Fri November 10, 2017
Gut Microbiome Can Influence Response to PD-1 Blockade in Melanoma
5:07 PM, Fri November 10, 2017
The Tumor Microenvironment Mediates Immunotherapy Response
4:38 PM, Fri November 10, 2017
Exploring the Efficacy of Pembrolizumab in Sarcoma Subtypes
6:33 PM, Thu August 31, 2017
Efficacy and Biomarker Results for Pembrolizumab in Soft Tissue and Bone Sarcomas
10:15 PM, Fri June 2, 2017
